Many a seasoned and sophisticated biopharma executive have described to me the reality of when an entity does not need to raise capital it should because at some point it will be needed, and by not needing it, the situation may, just may…lend itself to perhaps lowering the cost of capital due in part to [...]

• 454http://clsdf.com/2009/10/allos-get-it-when-you-can/Allos+%7C+Get+it+When+You+Can...2009-10-07+14%3A08%3A00admin

Inviragen (Ft. Collins, CO) a preclinical-stage vaccine company focused on emerging global infectious diseases, closed a $15M Series A financing and in the process merged the assets of Singapore-based SingVax. Participants in the round include Charter Life Sciences, Venture Investors, Bio*One Capital and Phillip Private Equity. This initial round of institutional capital comes on the [...]

• 453http://clsdf.com/2009/10/inviragen-series-a-15m-and-ma/Inviragen+%7C+Series+A+%2415M+and+M%26amp%3BA2009-10-07+13%3A11%3A00admin